Evidence map›Paper›PMID 20438881›Full record

ReviewAgeing research reviews2010

Models of accelerated sarcopenia: critical pieces for solving the puzzle of age-related muscle atrophy.

Thomas W Buford, Stephen D Anton, Andrew R Judge, Emanuele Marzetti, Stephanie E Wohlgemuth, Christy S Carter, Christiaan Leeuwenburgh, Marco Pahor, Todd M Manini

Open access · greenAbstract readReview
In one paragraph

Review in Ageing research reviews, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
149citing papers in PubMed, 4 pooled it
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

149 citing papers in PubMed, 4 syntheses or guidelines pooled it, 298 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Circulating Mediators of Apoptosis and Inflammation in Aging; Physical Exercise Intervention.International journal of environmental research and public health · 2021
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Sarcopenia during androgen-deprivation therapy for prostate cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012
    Trial
  14. Article
  15. Article
  16. Article
  17. What Is 'Muscle Health'? A Narrative Review and Conceptual Framework.Journal of functional morphology and kinesiology · 2025
    Review
  18. Frailty Assessment in an Aging Mouse Model.Journal of visualized experiments : JoVE · 2025
    Article
  19. Article
  20. Article

89 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Thomas W BufordInstitute on Aging, University of Florida, Gainesville, FL 32611, United States. tbuford@aging.ufl.edu
Stephen D Anton
Andrew R Judge
Emanuele Marzetti
Stephanie E Wohlgemuth
Christy S Carter
Christiaan Leeuwenburgh
Marco Pahor
Todd M Manini
Institute on Aging · USUniversity of Florida · US

Funding

University of Florida Older Americans Independence Center (OAIC)P30AG028740 · NIA · UNIVERSITY OF FLORIDA · PI CHRISTIAAN LEEUWENBURGH · 2007 to 2026
$22.8M
NIA NIH HHS P30 AG028740
6 · The paper itself

Abstract

Sarcopenia, the age-related loss of skeletal muscle mass, is a significant public health concern that continues to grow in relevance as the population ages. Certain conditions have the strong potential to coincide with sarcopenia to accelerate the progression of muscle atrophy in older adults. Among these conditions are co-morbid diseases common to older individuals such as cancer, kidney disease, diabetes, and peripheral artery disease. Furthermore, behaviors such as poor nutrition and physical inactivity are well-known to contribute to sarcopenia development. However, we argue that these behaviors are not inherent to the development of sarcopenia but rather accelerate its progression. In the present review, we discuss how these factors affect systemic and cellular mechanisms that contribute to skeletal muscle atrophy. In addition, we describe gaps in the literature concerning the role of these factors in accelerating sarcopenia progression. Elucidating biochemical pathways related to accelerated muscle atrophy may allow for improved discovery of therapeutic treatments related to sarcopenia.

Indexed as

AgingSarcopeniaAccelerationAgedAged, 80 and overApoptosisComorbidityDiabetes MellitusFeeding BehaviorHealth Knowledge, Attitudes, PracticeHumansKidney DiseasesModels, BiologicalMotor ActivityMuscle, SkeletalNeoplasms

Identifiers

PMID20438881
PMCPMC3788572
OpenAlexW1967880601

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.